Literature DB >> 26621143

Concomitant Phosphodiesterase 5 Inhibition Enhances Myocardial Protection by Inhaled Nitric Oxide in Ischemia-Reperfusion Injury.

Arpad Lux1, Peter Pokreisz1, Melissa Swinnen1, Ellen Caluwe1, Hilde Gillijns1, Zsolt Szelid1, Bela Merkely1, Stefan P Janssens2.   

Abstract

Enhanced cyclic guanosine monophosphate (cGMP) signaling may attenuate myocardial ischemia-reperfusion injury (I/R) and improve left ventricular (LV) functional recovery after myocardial infarction (MI). We investigated the cardioprotection afforded by inhaled NO (iNO), the phosphodiesterase 5 (PDE5)-specific inhibitor tadalafil (TAD), or their combination (iNO+TAD) in C57Bl6J mice subjected to 6-minute left anterior descending artery ligation followed by reperfusion. We measured plasma and cardiac concentrations of cGMP during early reperfusion, quantified myocardial necrosis and inflammation by serial troponin-I (TnI) and myeloperoxidase-positive cell infiltration at day 3, and evaluated LV function and remodeling after 4 weeks using echocardiography and pressure-conductance catheterization. Administration of iNO, TAD, or both during I/R was safe and hemodynamically well tolerated. Compared with untreated mice (CON), only iNO+TAD increased plasma and cardiac-cGMP levels during early reperfusion (80 ± 12 versus 36 ± 6 pmol/ml and 0.15 ± 0.02 versus 0.05 ± 0.01 pmol/mg protein, P < 0.05 for both). Moreover, iNO+TAD reduced TnI at 4 hours to a greater extent (P < 0.001 versus CON) than either alone (P < 0.05 versus CON) and was associated with significantly less myocardial inflammatory cell infiltration at day 3. After 4 weeks and compared with CON, iNO+TAD was associated with increased fractional shortening (43 ± 1 versus 33 ± 2%, P < 0.01), larger stroke volumes (14.9 ± 1.2 versus 10.2 ± 0.9 μl, P < 0.05), enhanced septal and posterior wall thickening (P < 0.05 and P < 0.001, respectively), and attenuated LV dilatation (P < 0.001), whereas iNO or TAD alone conferred less benefit. Thus, iNO+TAD has superior efficacy to limit early reperfusion injury and attenuate adverse LV remodeling. Combination of inhaled NO with a long-acting PDE5 inhibitor may represent a promising strategy to reduce ischemic damage following reperfusion and better preserve LV function.
Copyright © 2016 by The American Society for Pharmacology and Experimental Therapeutics.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26621143     DOI: 10.1124/jpet.115.227850

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  6 in total

Review 1.  Inhaled pulmonary vasodilators: a narrative review.

Authors:  Kai Liu; Huan Wang; Shen-Ji Yu; Guo-Wei Tu; Zhe Luo
Journal:  Ann Transl Med       Date:  2021-04

2.  Development of a portable mini-generator to safely produce nitric oxide for the treatment of infants with pulmonary hypertension.

Authors:  Binglan Yu; Michele Ferrari; Grigorij Schleifer; Aron H Blaesi; Martin Wepler; Warren M Zapol; Donald B Bloch
Journal:  Nitric Oxide       Date:  2018-02-24       Impact factor: 4.427

3.  Phosphodiesterase-5a Knock-out Suppresses Inflammation by Down-Regulating Adhesion Molecules in Cardiac Rupture Following Myocardial Infarction.

Authors:  Siyi Li; Youcai Ma; Yan Yan; Mengwen Yan; Xiao Wang; Wei Gong; Shaoping Nie
Journal:  J Cardiovasc Transl Res       Date:  2021-01-26       Impact factor: 4.132

4.  Inhaled nitric oxide before induction of anesthesia in patients with pulmonary hypertension.

Authors:  Vedat Eljezi; Laetitia Rochette; Christian Dualé; Bruno Pereira; Henri Boby; Jean Michel Constantin
Journal:  Ann Card Anaesth       Date:  2021 Oct-Dec

5.  Tadalafil, a long acting phosphodiesterase inhibitor, promotes bone marrow stem cell survival and their homing into ischemic myocardium for cardiac repair.

Authors:  Ibrahim Elmadbouh; Muhammad Ashraf
Journal:  Physiol Rep       Date:  2017-11

Review 6.  cGMP at the centre of attention: emerging strategies for activating the cardioprotective PKG pathway.

Authors:  Min Park; Peter Sandner; Thomas Krieg
Journal:  Basic Res Cardiol       Date:  2018-05-15       Impact factor: 17.165

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.